Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events
- PMID: 38604986
- DOI: 10.1111/bcp.16067
Validating use of diagnostic codes in Canadian administrative data for identification of adverse drug events
Abstract
Aims: While diagnostic codes from administrative health data might be a valuable source to identify adverse drug events (ADEs), their ability to identify unintended harms remains unclear. We validated claims-based diagnosis codes for ADEs based on events identified in a prospective cohort study and assessed whether key attributes predicted their documentation in administrative data.
Methods: This was a retrospective analysis of 3 prospective cohorts in British Columbia, from 2008 to 2015 (n = 13 969). We linked prospectively identified ADEs to administrative insurance data to examine the sensitivity and specificity of different diagnostic code schemes. We used logistic regression to assess which key attributes (e.g., type of event, symptoms and culprit medications) were associated with better documentation of ADEs in administrative data.
Results: Among 1178 diagnosed events, the sensitivity of the diagnostic codes in administrative data ranged from 3.4 to 52.6%, depending on the database and codes used. We found that documentation was worse for certain types of ADEs (dose-related: odds ratio [OR]: 0.32, 95% confidence interval [CI]: 0.15, 0.69; nonadherence events (OR: 0.35, 95% CI: 0.20, 0.62), and better for those experiencing arrhythmias (OR: 4.19, 95% CI: 0.96, 18.28).
Conclusion: ADEs were not well documented in administrative data. Alternative methods should be explored to capture ADEs for health research.
Keywords: administrative data; adverse drug event; adverse drug reaction; drug safety; pharmacovigilance.
© 2024 The Authors. British Journal of Clinical Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.
References
REFERENCES
-
- Hohl CM, Badke K, Zhao A, et al. Prospective validation of clinical criteria to identify emergency department patients at high risk for adverse drug events. Acad Emerg Med. 2018;25(9):1015‐1026. doi:10.1111/acem.13407
-
- Zed PJ, Abu‐Laban RB, Balen RM, et al. Incidence, severity and preventability of medication‐related visits to the emergency dep0061rtment: a prospective study. CMAJ. 2008;178(12):1563‐1569. doi:10.1503/cmaj.071594
-
- Sorensen SV, Dewilde S, Singer DE, Goldhaber SZ, Monz BU, Plumb JM. Cost‐effectiveness of warfarin: Trial versus “real‐world” stroke prevention in atrial fibrillation. Am Heart J. 2009;157(6):1064‐1073. doi:10.1016/j.ahj.2009.03.022
-
- Staa T‐P, Leufkens HG, Zhang B, Smeeth L. A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective Cox‐2 inhibitors as an example. PLoS Med. 2009;6(12):e1000194. doi:10.1371/journal.pmed.1000194
-
- Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. American Society of Clinical Oncology educational book American Society of Clinical Oncology Annual Meeting. 2016;35(36):185‐198. doi:10.1200/EDBK_156686
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
